Philadelphia University + Thomas Jefferson University

Knudsen, Karen

< Back



Karen E. Knudsen, PhD

Contact Dr. Knudsen

233 South 10th Street
Suite 1008
Philadelphia, PA 19107

(215) 503-8574

Research and Clinical Interests

Translational prostate cancer research, cell cycle control, hormonal control of gene transcription, chromatin remodeling. Prostate cancer is the most commonly diagnosed malignancy in the Unites States and the second leading cause of cancer death in men. Early prostate cancers require androgen to survive and proliferate; this dependence is exploited in treatment for disseminated disease. Wherein androgen ablation in the first line of therapeutic intervention. Although these regimens are initially effective, tumors ultimately recur due to reactivation of androgen receptor (AR) signaling, causing treatment failure and patient morbidity.

Despite the importance of understanding androgen action in the prostate, little is understood about the mechanisms underlying androgen dependence, and the means by which the androgen requirement is bypassed in relapsed tumors. My lab is dedicated to delineating the molecular mechanisms that govern these events. We currently have four main projects in the lab:

1. Regulation of AR dependent gene expression and cellular proliferation by cell cycle crosstalk in prostate cancer

2. Impact of SWI/SNF chromatin remodeling factors on AR function and prostate tumorigenesis

3. Impact of cell cycle deregulation on therapeutic efficacy

4. Role of endocrine disrupting compounds in circumventing the androgen requirement


Most Recent Peer-Reviewed Publications

  1. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells
  2. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  3. Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors
  4. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
  5. PARP Inhibitors in Prostate Cancer
  6. Sigma1 targeting to suppress aberrant androgen receptor signaling in prostate cancer
  7. Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle
  8. Cell cycle-coupled expansion of AR activity promotes cancer progression
  9. RB loss promotes prostate cancer metastasis
  10. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  11. There and back again: The middle earth of DNA repair
  12. Linking DNA Damage and Hormone Signaling Pathways in Cancer
  13. Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer
  14. Downregulation of critical oncogenes by the selective SK2 Inhibitor ABC294640 hinders prostate cancer progression
  15. Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
  16. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  17. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  18. Models of neuroendocrine prostate cancer
  19. Cell-cycle-dependent regulation of androgen receptor function
  20. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function